A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users

Completed · Phase 1 · Has a placebo group

Conditions studied: Recreational Drug Use, Prescription Drug Abuse (Not Dependent)

In brief

The purpose of this study is to assess the abuse potential of study drug lasmiditan. Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any active drug) to determine the potential for drug abuse. The dosages will be in tablet form and will be taken orally (by mouth). This study will last about 55 days, including screening. Screening will occur within 28 days prior to qualification phase.

Key facts

Study ID
NCT03286218
Run by
Eli Lilly and Company
People needed
96
Starts
2017-09-15
Expected to finish
2017-11-20
Last updated by the study team
2020-01-10

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.